CBG002 CAR-T Cell

CBG002 CAR-T cell · Carbiogene Therapeutics Co. Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CBG002 CAR-T Cell, covering 2024-11-26 to 2024-11-26. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma [Phase 1]